Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease.
Sebastian ZeissigElisa RosatiC Marie DowdsKonrad AdenJohannes BethgeBerenice SchulteWei Hung PanNeha MishraMaaz ZuhayraMarlies MarxMaren PaulsenAnne StrigliClaudio ConradDörthe SchuldtAnupam SinhaHenriette EbsenSabin-Christin KornellSusanna NikolausAlexander ArltDieter KabelitzMark EllrichmannUlf LützenPhilip C RosenstielAndre FrankeStefan SchreiberPublished in: Gut (2018)
NCT02694588.